"...Immutep have shown that by the
addition of Efti to an anti-PD-1 agent they are able to ‘rescue’ an additional 36% of patients that would otherwise have tumour progression – which
is powerful and relevant for pharma that continue to struggle with IO resistance and low overall treatment response rates (20-30%). The durability
of patient responses is a significant win for Immutep confirmed by this data readout. ..."
Say no more...
"...Immutep have shown that by the addition of Efti to an...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.015(3.57%) |
Mkt cap ! $517.1M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.5¢ | 42.0¢ | $1.348M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10725 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 14524 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
43.5¢ |
Change
0.015 ( 3.57 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 44.0¢ | 42.5¢ | 697373 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| IMM (ASX) Chart |